BOBÁĽ, Pavel, M. LASTOVICKOVA and J. BOBALOVA. The Role of ATRA, Natural Ligand of Retinoic Acid Receptors, on EMT-Related Proteins in Breast Cancer: Minireview. International Journal of Molecular Sciences. Basel: Multidisciplinary Digital Publishing Institute, 2021, vol. 22, No 24, p. 1-18. ISSN 1422-0067. Available from: https://dx.doi.org/10.3390/ijms222413345.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The Role of ATRA, Natural Ligand of Retinoic Acid Receptors, on EMT-Related Proteins in Breast Cancer: Minireview
Authors BOBÁĽ, Pavel (703 Slovakia, belonging to the institution), M. LASTOVICKOVA and J. BOBALOVA (guarantor).
Edition International Journal of Molecular Sciences, Basel, Multidisciplinary Digital Publishing Institute, 2021, 1422-0067.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 6.208
RIV identification code RIV/00216224:14160/21:00124008
Organization unit Faculty of Pharmacy
Doi http://dx.doi.org/10.3390/ijms222413345
UT WoS 000738236600001
Keywords in English breast cancer; EMT; protein; ATRA
Tags rivok, ÚChL
Tags International impact, Reviewed
Changed by Changed by: JUDr. Sabina Krejčiříková, učo 383857. Changed: 31/1/2022 15:47.
Abstract
The knowledge of the structure, function, and abundance of specific proteins related to the EMT process is essential for developing effective diagnostic approaches to cancer with the perspective of diagnosis and therapy of malignancies. The success of all-trans retinoic acid (ATRA) differentiation therapy in acute promyelocytic leukemia has stimulated studies in the treatment of other tumors with ATRA. This review will discuss the impact of ATRA use, emphasizing epithelial-mesenchymal transition (EMT) proteins in breast cancer, of which metastasis and recurrence are major causes of death.
Links
MUNI/A/1682/2020, interní kód MUName: Návrh, syntéza a hodnocení derivátů skupin léčiv s inhibiční enzymatickou aktivitou
Investor: Masaryk University
PrintDisplayed: 1/8/2024 02:18